Every 424B that eXoZymes Inc (EXOZ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow EXOZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXOZ filings page.
eXoZymes Inc. is offering 35,555 units, each unit consisting of two shares of common stock and one warrant, representing 71,110 shares and 35,555 warrants sold together at $18.00 per unit. The warrants are exercisable from June 5, 2027 through June 5, 2031 at an initial exercise price of $11.24, subject to a one-time reset to $0.001 if the company issues later shares at a lower price prior to June 5, 2027 and certain holding conditions are met.
The placement agent is MDB Capital, an affiliate and substantial shareholder (holding 4,136,426 shares; 43.9% pre-offering). Net proceeds to the company are estimated at approximately $565,206. Shares outstanding prior to the offering are 9,210,249; as adjusted shares outstanding after this offering will be 9,281,359. The company discloses substantial going-concern risk and expects additional capital needs.
eXoZymes Inc. is offering 592,270 shares of common stock and 296,135 warrants as units (two shares plus one warrant) pursuant to a prospectus supplement. Units are priced at $18.00 per unit; the offering includes a 45-day 15% over-allotment option. Each Warrant is exercisable beginning one year after the offering at $11.24 and expires five years after issuance, with a one-time exercise-price reset provision to $0.001 under specified conditions and a redemption feature at $0.01 per Warrant when the share price meets the stated trigger. Net proceeds are estimated at approximately $4,704,300 (or $5,447,891 if the over-allotment is exercised) to be used for developing the Company’s NCT program, next-in-line products, R&D, working capital and capital expenditures.
eXoZymes Inc. is conducting a proposed underwritten offering of units, each consisting of two shares of common stock and one warrant, under a preliminary prospectus supplement dated June 4, 2026. The filing states 8,478,992 shares outstanding and a public float value of $15,165,341 based on 8,478,992 shares and a per-share price of $11.70 as of April 10, 2026. MDB Capital Holdings is the largest pre-offering holder with 4,136,426 shares (representing 47.79%).
The units pair two common shares with one warrant exercisable beginning one year after issuance and expiring five years after issuance, subject to a potential exercise-price reset to $0.001 if the company issues equity at a lower price within one year. Warrants are redeemable for $0.01 under specified trading-price conditions. The offering includes a 45-day, up-to-15% overallotment option, a 7% underwriting discount, and underwriter warrants equal to 10% of shares and underlying securities sold.
eXoZymes Inc. is offering units consisting of two shares of common stock and one common-stock purchase warrant, together with separate Warrants exercisable for one share each. The prospectus supplement sets terms including a two-year warrant term, potential issuer call/redemption mechanics, and a 45-day 15% over-allotment option.
The filing discloses that MDB Capital Holdings beneficially holds 4,136,426 shares (47.79%) and that Lucid Capital Markets will act as the FINRA-qualified independent underwriter for a $175,000 fee. The company reports a public float of $15,165,341 based on 8,478,992 shares and a reference price of $11.70 as of April 10, 2026. Use of proceeds is stated for NCT program development, R&D, working capital and general corporate purposes.
eXoZymes Inc. filed a preliminary prospectus supplement to sell shares of its common stock under a shelf registration (Registration No. 333-292781). The offering size and per-share price are redacted in this excerpt. The lead underwriter, MDB Capital, is affiliated with a 47.79% holder, creating a FINRA Rule 5121 conflict; a qualified independent underwriter will participate.
The company states it will use net proceeds to advance its NCT program, related nutraceutical commercialization and R&D, and for general corporate purposes. The filing discloses pilot-scale NCT production at >99% purity and commercial scale-up plans, but many financial and offering specifics are redacted in the provided excerpt.
eXoZymes Inc. has put in place a shelf registration to offer up to $50,000,000 of securities, including common stock, preferred stock, debt securities, warrants, subscription rights and units, to be issued in one or more future offerings. The exact terms, pricing and mix of these securities will be set in separate prospectus supplements for each transaction and may involve sales directly by the company, through underwriters, dealers or agents, or a combination of these methods.
The company states that, unless specified otherwise in a supplement, net proceeds will be used for general corporate purposes and working capital, which may include capital spending, research and development, regulatory and clinical trial costs, technology or asset acquisitions and business expansion. eXoZymes’ common stock trades on the Nasdaq Capital Market under the symbol EXOZ, and as of January 23, 2026, there were 8,400,258 shares of common stock issued, with a closing price of $11.85 per share on that date.